Monte Rosa Therapeutics (GLUE) Revenue Growth (1y) (2025 - 2026)
Monte Rosa Therapeutics (GLUE) Revenue Growth (1y) (2025 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 96.43% |
| 10 | Monte Rosa Therapeutics | 2.28 Bn | 1.60 Bn | - | -94.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.94% |
| Dec 31, 2025 | -95.41% |
| Sep 30, 2025 | 1,527.60% |
| Jun 30, 2025 | 2,886.16% |
| Mar 31, 2025 | 7,882.05% |